Histogen launches aesthetics biz
This article was originally published in The Rose Sheet
Executive Summary
Skin-, hair- and nail-care products under development are built upon regenerative medicine company'sReGenica complex, extracted from proprietary bioreactor process in which newborn fibroblasts - connective tissue cells involved in wound healing - are grown under embryonic-like conditions. Composed of naturally secreted growth factors, antioxidants and other synergistic bio-products, Regenica was associated with improved overall skin condition, compared with control group, in 49-subject study when applied following an ablative cosmetic laser procedure. Follow-up studies are exploring the treatment's usefulness post-laser-resurfacing and in topical skin and hair anti-aging applications, firm says. "The market for next-generation, novel cosmeceuticals is rapidly evolving," notes Lawrence A. Rheins, Ph.D., president of new Histogen Aesthetics division. "There is a continuing need for adjunct palliative skin conditioning products for use following all sorts of minimally invasive cosmetic procedures ... by physicians engaged in aesthetic medicine." Histogen is optimistic that "robust controlled scientific data to support claims" will help it stand out from crowd. The Estee Lauder Companies/Allergan also made clinical validation a top priority in creating Clinique Medical skin care for patients undergoing non-surgical cosmetic procedures (1"The Rose Sheet" Oct. 20, 2008, p. 4)
You may also be interested in...
Lauder/Allergan Marriage Delivers Clinique Medical For Cosmetic Procedures
The Estee Lauder Companies has joined with pharmaceutical firm Allergan to launch Clinique Medical, a line of skin-care products designed to prepare skin for non-surgical cosmetic procedures and assist in the healing process, the firm says Oct. 15
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.